News about Drug Discovery & Development

Glenmark Pharma expand its OTC portfolio

Acquires approved ANDAs from Wockhardt

Drug Discovery & Development | 28/06/2022 | By Sudeep Soparkar |  803

Merck opens ?59 M CDMO facility to address critical cancer therapies

The 70,000 square foot facility, officially opened, brings 50 new jobs to the area

Drug Discovery & Development | 24/06/2022 | By Sudeep Soparkar |  788

Gericke ensures precise dosing operation with high-performance feeding unit

The right selection ensures recipe consistency and automated production to prevents product rejects

Drug Discovery & Development | 16/06/2022 | By Sudeep Soparkar |  495

I-Mab partners with MorphoSys

I-Mab partners with MorphoSys
Announces new license agreements for Felzartamab and TJ210

Drug Discovery & Development | 16/06/2022 | By Sudeep Soparkar |  900

Daiichi Sankyo's quizartinib plus chemotherapy improves OS in patients with AML

Quizartinib combined with standard induction and consolidation chemotherapy and then continued as a single agent demonstrated a 22.4 per cent reduction in the risk of death

Drug Discovery & Development | 13/06/2022 | By Sudeep Soparkar |  972

Autoimmune drug by Bristol Myers shows potential in lupus

Deucravacitinib is one of nine new drugs that Bristol Myers executives believe will help offset revenue losses

Drug Discovery & Development | 08/06/2022 | By Sudeep Soparkar |  932

PerkinElmer unveils ultrarapid whole-genome sequencing

The urWGS offering provides physicians with comprehensive, meaningful results in five days to help inform clinical management and improve outcomes

Drug Discovery & Development | 08/06/2022 | By Sudeep Soparkar |  619

BioNTech 2nd phase of Covid 19 trials completed

The vaccine, based on messenger RNA (mRNA) technology, is one of the most widely used worldwide against COVID, but has yet to receive an approval in China, which has relied only on domestically-developed vaccine

Drug Discovery & Development | 12/05/2022 | By Sudeep Soparkar |  792

US FDA approval for Incyte's Olumiant

Eli Lilly and Company and Incyte announced the US Food and Drug Administration (FDA) has approved Olumiant (baricitinib) for the treatment of Covid-19 in hospitalized adults requiring supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) with a recommended dose of 4-mg once daily for 14 days.

Drug Discovery & Development | 12/05/2022 | By Sudeep Soparkar |  961

The Dutch company MIMETAS expanded its license to the HUB Organoid Technology to include all organs

These miniature organs are used to develop therapies against incurable diseases.

Drug Discovery & Development | 11/05/2022 | By Content editor |  1237